Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study

Abstract Background Pembrolizumab plus lenvatinib is a treatment option for metastatic Renal Cell Carcinoma (mRCC). In the ARON-1 study we investigated we the real-world experiences gained from the use of this combination for mRCC. Methods We retrospectively investigated real-world clinical outcomes...

Full description

Saved in:
Bibliographic Details
Main Authors: Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, Maria T. Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Zin W. Myint, Giuseppe Fornarini, Thomas Buttner, Se Hoon Park, Yüksel Ürün, Ugo De Giorgi, Renate Pichler, Pasquale Rescigno, Tomas Buchler, Hana Studentova, Bohuslav Melichar, Jawaher Ansari, Veronica Mollica, Jakub Kucharz, Mimma Rizzo, Alessandro Rizzo, Ray Manneh Kopp, Sebastiano Buti, Fernando Sabino Marques Monteiro, Andrey Soares, Aristotelis Bamias, Matteo Santoni
Format: Article
Language:English
Published: Springer 2025-05-01
Series:Cancer Immunology, Immunotherapy
Subjects:
ARON- 1
Immune-combinations
Lenvatinib
Pembrolizumab
Real-world data
Renal cell carcinoma
Online Access:https://doi.org/10.1007/s00262-025-04019-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04019-x

Similar Items